Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR

被引：6

作者：

Zhang, Jian ^{[1
]}

Yang, Yaoyao ^{[1
]}

Zhao, Jing ^{[2
]}

Shi, Lifang ^{[1
]}

Xu, Yanhua ^{[1
]}

Yu, Kaikai ^{[3
]}

Guo, Chongyong ^{[4
]}

机构：

[1] Binzhou Peoples Hosp, Dept Pathol, 515 Huanghe 7th Rd, Binzhou 256600, Shandong, Peoples R China

[2] Binzhou Peoples Hosp, Dept Rehabil Training, 515 Huanghe 7th Rd, Binzhou 256600, Shandong, Peoples R China

[3] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China

[4] Binzhou Peoples Hosp, Dept Surg, 515 Huanghe 7th Rd, Binzhou 256600, Shandong, Peoples R China

来源：

PATHOLOGY RESEARCH AND PRACTICE | 2019年 / 215卷 / 04期

关键词：

PTC; BRAFV600E; Lymph node metastasis; PHASE-II; B-RAF; CANCER; SORAFENIB; EFFICACY; MANAGEMENT; THERAPIES; GENE;

D O I：

10.1016/j.prp.2019.01.006

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Objectives: To figure out that if there is a consistency relationship of the BRAF(V600E) mutation in matched-lymph node metastasis and original papillary thyroid carcinoma (PTC) specimen for the same patient. Methods: We collected the specimen of thyroids and matched-lymph node metastases of PTCs and tested the BRAF(V600E) mutation status with amplification refractory mutation system (ARMS) PCR. Results: 20 patients with PTC and metastasis lymph node were hired. In this cohort, 16 (80%) patients had the same BRAF genetic mutation status in thyroid and metastasis, and the other 4 (20%) had an inconsistent situation. Conclusions: Within our cohort, the data suggested that wild-type BRAF(V600E) oncogene in thyroid primary tumor does not rule out its mutation in lymph node metastasis, and vice versa.

引用

页码：761 / 765

页数：5

共 31 条

[1] Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population [J].

Ahmed, Merina ;

Barbachano, Yolanda ;

Riddell, Angela ;

Hickey, Jen ;

Newbold, Katie L. ;

Viros, Amaya ;

Harrington, Kevin J. ;

Marais, Richard ;

Nutting, Christopher M. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 165 (02) :315-322

[2] Iodide symporter gene expression in human thyroid tumors [J].

Arturi, F ;

Russo, D ;

Schlumberger, M ;

du Villard, JA ;

Caillou, B ;

Vigneri, P ;

Wicker, R ;

Chiefari, E ;

Suarez, HG ;

Filetti, S .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (07) :2493-2496

[3] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J].

Brose, Marcia S. ;

Nutting, Christopher M. ;

Jarzab, Barbara ;

Elisei, Rossella ;

Siena, Salvatore ;

Bastholt, Lars ;

de la Fouchardiere, Christelle ;

Pacini, Furio ;

Paschke, Ralf ;

Shong, Young Kee ;

Sherman, Steven I. ;

Smit, Johannes W. A. ;

Chung, John ;

Kappeler, Christian ;

Pena, Carol ;

Molnar, Istvan ;

Schlumberger, Martin J. .

LANCET, 2014, 384 (9940) :319-328

[4] Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience [J].

Cabanillas, Maria E. ;

Waguespack, Steven G. ;

Bronstein, Yulia ;

Williams, Michelle D. ;

Feng, Lei ;

Hernandez, Mike ;

Lopez, Adriana ;

Sherman, Steven I. ;

Busaidy, Naifa L. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06) :2588-2595

[5] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[6] New Therapies for Dedifferentiated Papillary Thyroid Cancer [J].

Fallahi, Poupak ;

Mazzi, Valeria ;

Vita, Roberto ;

Ferrari, Silvia Martina ;

Materazzi, Gabriele ;

Galleri, David ;

Benvenga, Salvatore ;

Miccoli, Paolo ;

Antonelli, Alessandro .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (03) :6153-6182

[7] BRAF mutations in papillary carcinomas of the thyroid [J].

Fukushima, T ;

Suzuki, S ;

Mashiko, M ;

Ohtake, T ;

Endo, Y ;

Takebayashi, Y ;

Sekikawa, K ;

Hagiwara, K ;

Takenoshita, S .

ONCOGENE, 2003, 22 (41) :6455-6457

[8] Guilty as charged: B-RAF is a human oncogene [J].

Garnett, MJ ;

Marais, R .

CANCER CELL, 2004, 6 (04) :313-319

[9] The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma [J].

Giannini, Riccardo ;

Ugolini, Clara ;

Lupi, Cristiana ;

Proietti, Agnese ;

Elisei, Rossella ;

Salvatore, Giuliana ;

Berti, Piero ;

Materazzi, Gabriele ;

Miccoli, Paolo ;

Santoro, Massimo ;

Basolo, Fulvio .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09) :3511-3516

[10] Cancer Statistics, 2009 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Hao, Yongping ;

Xu, Jiaquan ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2009, 59 (04) :225-249

← 1 2 3 4 →